+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gaucher Disease Drugs Market Size, Share & Trends Analysis Report by Type (Type 1, Type 2, Type 3, Others) By Therapy (Enzyme Replacement Therapy, Substrate Replacement Therapy, Others), Region, and Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 84 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 5921074
Description Jump to:
The global gaucher disease drugs market size is expected to reach USD 2.03 billion by 2030, expanding at a CAGR of 2.6% from 2023 to 2030. The growing prevalence of the disease and increasing research and development activities in the field are likely to help the market in gaining momentum over the coming years. With high unmet needs, there is a strong need for the development of novel treatments with improved efficacy in neuronopathic complications, convenient dosage, and reduced cost.

Gaucher disease is a genetic metabolic disorder, caused by mutations in GBA gene. People with Gaucher disease produce low glucocerebrosidase (GCase), an enzyme required to degrade glucocerebroside. Excess accumulation of lipids in spleen, liver, kidney, brain, lungs, and bone marrow impedes the normal functioning of the organs.

In spite of being the most prevalent lysosomal storage disorder, Gaucher disease is a rare condition with an average prevalence of 1 in 100,000 individuals. However, certain ethnic races such as Ashkenazi Jews are more susceptible to this disorder. Ashkenazi Jews have an average disease prevalence of 1 in 500 individuals.

Currently, type 1 is the most common form of Gaucher disease. This condition is nonneuronopathic in nature, as it does not affect the central nervous system (CNS). Type 1 GD commanded more than 75.0% of the market in 2017. It is estimated to retain its position through 2025. Type 2 and type 3 are not as common as type 1.

On the basis of treatment, enzyme replacement therapy (ERT) was the leading revenue contributor in the market in 2017. The growth of the segment can be attributed to the strong sales of Cerezyme and Vpriv. However, there has been an increase in inclination towards substrate replacement therapy (SRT), spearheaded by Cerdelga and Zavesca. ERT is mostly indicated for type 1 and type 3 (to address issues unrelated to the CNS), as replacement enzymes cannot penetrate blood brain barrier. Additionally, there is no effective treatment for type 2.

Gaucher Disease Drugs Market Report Highlights

  • Type 2 is the rarest of the three forms of GD, with an average mortality rate of less than two years
  • Enzyme replacement therapy dominated the treatment landscape, headed by Sanofi Genzyme’s Cerezyme. However, GD treatment is witnessing a shift towards substrate replacement therapy
  • The U.S. spearheaded the major markets, in terms of sales as well as disease burden. The country will continue to dominate the market through 2030, on account of widening the patient base and easy accessibility to treatments
  • Some of the prominent companies operating in the market are Sanofi Genzyme, Shire, Pfizer, and Johnson & Johnson

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Type
1.1.2. Therapy
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Therapy outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Gaucher Disease Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Gaucher Disease Drugs Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Gaucher Disease Drugs: Type Estimates & Trend Analysis
4.1. Gaucher Disease Drugs Market: Key Takeaways
4.2. Gaucher Disease Drugs Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Type 1
4.3.1. Type 1 market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Type 2
4.4.1. Type 2 market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Type 3
4.5.1. Type 3 market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Others
4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Gaucher Disease Drugs: Therapy Estimates & Trend Analysis
5.1. Gaucher Disease Drugs Market: Key Takeaways
5.2. Gaucher Disease Drugs Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Enzyme Replacement Therapy
5.3.1. Enzyme replacement therapy market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Substrate Replacement Therapy
5.4.1. Substrate replacement therapy market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Others
5.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Gaucher Disease Drugs Market: Regional Estimates & Trend Analysis
6.1. Regional Outlook
6.2. Gaucher Disease Drugs Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5. Asia-Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Sanofi
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Takeda Pharmaceutical Company Limited
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Pfizer Inc
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Johnson & Johnson Services, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. ERAD Therapeutic
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 3 North America Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 4 North America Gaucher disease drugs market, by region, 2018-2030 (USD Million)
Table 5 U.S. Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 6 U.S. Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 7 Canada Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 8 Canada Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 9 Europe Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 10 Europe Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 11 Europe Gaucher disease drugs market, by region, 2018-2030 (USD Million)
Table 12 UK Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 13 UK Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 14 Germany Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 15 Germany Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 16 France Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 17 France Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 18 Italy Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 19 Italy Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 20 Spain Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 21 Spain Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 22 Sweden Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 23 Sweden Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 24 Norway Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 25 Norway Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 26 Denmark Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 27 Denmark Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 28 Asia-Pacific Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 29 Asia-Pacific Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 30 Asia-Pacific Gaucher disease drugs market, by region, 2018-2030 (USD Million)
Table 31 China Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 32 China Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 33 Japan Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 34 Japan Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 35 India Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 36 India Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 37 Australia Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 38 Australia Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 39 Thailand Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 40 Thailand Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 41 South Korea Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 42 South Korea Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 43 Latin America Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 44 Latin America Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 45 Latin America Gaucher disease drugs market, by region, 2018-2030 (USD Million)
Table 46 Brazil Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 47 Brazil Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 48 Mexico Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 49 Mexico Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 50 Argentina Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 51 Argentina Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 52 Middle East and Africa Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 53 Middle East and Africa Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 54 Middle East and Africa Gaucher disease drugs market, by region, 2018-2030 (USD Million)
Table 55 Saudi Arabia Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 56 Saudi Arabia Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 57 South Africa Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 58 South Africa Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 59 UAE Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 60 UAE Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
Table 61 Kuwait Gaucher disease drugs market, by type, 2018-2030 (USD Million)
Table 62 Kuwait Gaucher disease drugs market, by therapy, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value-chain-based sizing & forecasting
Figure 6 QFD modeling for market share assessment
Figure 7 Market formulation & validation
Figure 8 Gaucher disease drugs: Market outlook
Figure 9 Gaucher disease drugs: Competitive insights
Figure 10 Parent market outlook
Figure 11 Related/ancillary market outlook
Figure 12 Penetration and growth prospect mapping
Figure 13 Industry value chain analysis
Figure 14 Gaucher disease drugs market driver impact
Figure 15 Gaucher disease drugs market restraint impact
Figure 16 Gaucher disease drugs market strategic initiatives analysis
Figure 17 Gaucher disease drugs market: Type movement analysis
Figure 18 Gaucher disease drugs market: Type outlook and key takeaways
Figure 19 Type 1 market estimates and forecasts, 2018-2030 (USD Million)
Figure 20 Type 2 market estimates and forecasts, 2018-2030 (USD Million)
Figure 21 Type 3 market estimates and forecasts, 2018-2030 (USD Million)
Figure 22 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 23 Gaucher disease drugs market: Therapy movement analysis
Figure 24 Gaucher disease drugs market: Therapy outlook and key takeaways
Figure 25 Enzyme replacement therapy market estimates and forecasts, 2018-2030 (USD Million)
Figure 26 Substrate replacement therapy market estimates and forecasts, 2018-2030 (USD Million)
Figure 27 Others market estimates and forecasts, 2018-2030 (USD Million)
Figure 28 Global gaucher disease drugs market: Regional movement analysis
Figure 29 Global gaucher disease drugs market: Regional outlook and key takeaways
Figure 30 North America market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Figure 32 Canada market estimates and forecasts, 2018-2030 (USD Million)
Figure 33 Europe market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 UK market estimates and forecasts, 2018-2030 (USD Million)
Figure 35 Germany market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 France market estimates and forecasts, 2018-2030 (USD Million)
Figure 37 Italy market estimates and forecasts, 2018-2030 (USD Million)
Figure 38 Spain market estimates and forecasts, 2018-2030 (USD Million)
Figure 39 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Figure 40 Norway market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Figure 42 Asia-Pacific market estimates and forecasts, 2018-2030 (USD Million)
Figure 43 Japan market estimates and forecasts, 2018-2030 (USD Million)
Figure 44 China market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 India market estimates and forecasts, 2018-2030 (USD Million)
Figure 46 Australia market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Figure 48 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Figure 49 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Figure 50 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Figure 51 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Figure 52 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Figure 53 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 54 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Figure 55 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 56 UAE market estimates and forecasts, 2018-2030 (USD Million)
Figure 57 Kuwait market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc
  • Johnson & Johnson Services, Inc.
  • ERAD Therapeutic

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages84
PublishedDecember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 1.65 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.03 Billion
Compound Annual Growth Rate2.6%
Regions CoveredGlobal
No. of Companies Mentioned5

Related Topics

Related Reports

Gaucher Disease Treatment Market by Type, Treatment, Diagnosis, Distribution Channel - Global Forecast 2025-2030 - Product Image

Gaucher Disease Treatment Market by Type, Treatment, Diagnosis, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Gaucher Disease Drug Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Gaucher Disease Drug Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Gaucher Disease Treatment - Global Strategic Business Report - Product Image

Gaucher Disease Treatment - Global Strategic Business Report

  • Report
  • 194 Pages
  • Global
From
Gaucher Disease Market by Type, Diagnosis and Treatment, End User, and Region 2024-2032 - Product Image

Gaucher Disease Market by Type, Diagnosis and Treatment, End User, and Region 2024-2032

  • Report
  • 138 Pages
  • Global
From
Gaucher's disease - Pipeline Insight, 2024 - Product Image

Gaucher's disease - Pipeline Insight, 2024

  • Clinical Trials
  • 50 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.